Some examples include anti-VEGF agents that have longer durations of action, ankyrin repeat protein (DARPin)-based therapy that binds all VEGF isoforms, bispecific anti-VEGF/angiopoietin (Ang)-2 therapies, anti-PDGF and anti-integrin therapies, Rho-kinase inhibitors, the port delivery system, steroids, gene therapies for the retina and uveitis and glaucoma, RhO-kinase (ROCK) inhibitors, implants and plugs, selective laser trabeculoplasty, and minimally invasive glaucoma surgeries [21,22]. The gene discussed is VEGFA; the disease is uveitis.